Table 2.
Unadjusted outcome data
| Variable | Overall (n = 1397) | Nonstatin group (n = 1,178) | Statin group (n = 219) | P value |
|---|---|---|---|---|
| Organ failure | ||||
| On or after day of first statin administration | 359/1,376 (26.1%) | 292/1,178 (24.8%) | 67/198 (33.8%) | 0.007 |
| At least 1 day after first statin administration | 344/1,361 (25.3%) | 292/1,178 (24.8%) | 52/183 (28.4%) | 0.29 |
| Days to organ failure | 3 (2, 5) (n = 359) | 3 (2, 5) (n = 292) | 3 (3, 4) (n = 67) | 0.63 |
| Duration of organ failurea | 2 (1, 5) (n = 359) | 2 (1, 5) (n = 292) | 2 (1, 5) (n = 67) | 0.77 |
| Safety | ||||
| Hepatic failureb | 112/1,392 (8.0%) | 89/1,178 (7.6%) | 23/214 (10.8%) | 0.11 |
| Days to hepatic failure | 4 (3,8) (n = 112) | 5 (3, 8) (n = 89) | 4 (3, 6) (n = 23) | 0.46 |
| Duration of hepatic failure | 1.5 (1, 3) (n = 112) | 2 (1, 3) (n = 89) | 1 (1, 4) (n = 23) | 0.84 |
| ALT > 165 IU/lc | 77/1,313 (5.9%) | 54/1,115 (4.8%) | 23/198 (11.6%) | 0.0002 |
| Days to ALT > 165 IU/l | 7 (4, 11) (n = 77) | 6 (4, 11) (n = 54) | 8 (5, 12) (n = 23) | 0.35 |
| Duration of ALT > 165 IU/l | 3 (1, 4) (n = 77) | 2 (1, 4) (n = 54) | 3 (1, 4) (n = 23) | 0.66 |
| Maximum ALT | 35 (19, 73) (n = 1,292) | 33 (18, 69) (n = 1,094) | 50 (28, 110) (n = 198) | < 0.0001 |
| Other outcomes | ||||
| ICU mortality | 177/1,397 (12.7%) | 149/1,178 (12.7%) | 28/219 (12.8%) | 0.96 |
| Hospital mortality | 270/1,397 (19.3%) | 221/1,178 (18.8%) | 49/219 (22.4%) | 0.21 |
| ICU length of stay | 5 (3, 10) (n = 1,397) | 4 (3, 9) (n = 1,178) | 7 (4, 15) (n = 219) | < 0.0001 |
| Hospital length of stay | 15 (8, 33) (n = 1,397) | 14 (7, 31) (n = 1,178) | 21 (12, 43) (n = 219) | < 0.0001 |
Data expressed as mean ± standard deviation, median (interquartile range), or number (percentage). ALT, alanine transferase; ICU, intensive care unit. aIncludes four patients in the statin group who had a Sequential Organ Failure Assessment (SOFA) score (hepatic) ≥3 on the day of first statin administration. bNew hepatic failure on the day of or after the first day of statin administration (defined as hepatic SOFA score ≥3) or an increase of bilirubin by ≥1.5 times from baseline to a value ≥20 mmol/l. Missing bilirubin values were assumed to be normal. cExcludes those in statin group with ALT > 165 IU/l at baseline or occurring before the first statin administration. Missing ALT values were assumed to be normal.